Evidence for the Immunosuppressive Potential of Calcineurin
Inhibitor-Sparing Regimens in Liver Transplant Recipients with
Impaired Renal Function
Table 1
Patient characteristics at living donor liver transplantation.
Non-RI group ()
RI group ()
value
(eGFR (mL/min/1.73 m2))
(94.8 ± 26.9)
(42.5 ± 15.9)
Age at LT (years)
49.2 ± 11.5
52.9 ± 9.0
0.23
Male sex—n (%)
21 (51.2)
13 (68.4)
0.21
Primary diagnosis—n (%)
0.63
HBV
15 (36.6)
9 (47.4)
Alcoholic
8 (19.5)
5 (26.3)
AIH
4 (9.8)
1 (5.3)
Others
14 (34.1)
4 (21.1)
MELD
16.5 ± 7.1
24.7 ± 10.7
< 0.01
eGFR at 1st year after LT (mL/min/1.73 m2)
77.2 ± 28.2
60.1 ± 13.5
< 0.01
eGFR > 60 at 1st year after LT—n (%)
26 (72.2)
10 (58.8)
0.33
AR within 1st year—n (%)
10 (24.4)
5 (26.3)
0.87
Bacterial infections—n (%)
13 (31.7)
8 (42.1)
0.43
Fungal infections—n (%)
4 (9.8)
4 (21.1)
0.23
CMV infections—n (%)
10 (24.4)
7 (36.8)
0.32
RI, renal insufficiency; LT, liver transplantation; HBV, hepatitis B virus; AIH, Autoimmune hepatitis; eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease; AR, acute rejection; CMV, cytomegalovirus. Data are expressed as means ± standard deviation. Difference with was considered significant.
